Top Markets
Coin of the day
CNS Pharmaceuticals, Inc. CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc.

CNSP
Rankning i aktier #33273
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily... CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
Aktiekurs
$5.47
Senast synkroniserad: 2026-08-14
Marknadsvärde
$7.99M
Förändring (1 dag)
6.21%
Förändring (1 år)
7.47%
Land
US
Handel CNS Pharmaceuticals, Inc. (CNSP)

Kategori

Aktiekurshistorik för CNS Pharmaceuticals, Inc. (CNSP)
Högsta slutkurs: $5.27 den 2026-08-01

Lägsta slutkurs: $3.79M den 2019-11-01
Aktiekurshistorik för CNS Pharmaceuticals, Inc. från 2019 till 2026
Årlig aktiekursutveckling
År Prestanda
2026 (TTM) -16.52%
2025 -89.84%
2024 -99.87%
2023 -34.43%
2022 -90.86%
2021 -58.90%
2020 -43.49%
2019 0.00%
Aktiekurs för liknande företag eller konkurrenter
Företag Aktiekurs Förändring 1år% Land
$505.24 28.63%
US
$846.09 29.41%
NL
$737.68 7.34%
CH
$1.07K -6.40%
KR
$255.62 13.43%
BE